Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 4/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | PGK1 | P00558 | 3/20 | 0.34 |
| ▸ | PGK2 | P07205 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8957065 | 0.68 | ACP3 (0.68) | ACP3CES2PGK1PGK2RXRA | |
| SCHEMBL17045185 | 0.68 | MEN1 (0.39) | ACP3CA12 | |
| SCHEMBL18911558 | 0.68 | MEN1 (0.39) | ACP3CA12 | |
| SCHEMBL24952555 | 0.68 | CES2 (0.41) | CES2RXRARXRBRXRG | |
| SCHEMBL21048412 | 0.67 | DYRK1A (0.45) | — | |
| SCHEMBL14420983 | 0.66 | CES2 (0.39) | CES2RXRARXRBRXRG | |
| SCHEMBL28875411 | 0.65 | PGK1 (0.50) | ACP3CES2PGK1PGK2CA12 | |
| SCHEMBL8927441 | 0.64 | CES2 (0.53) | ACP3CES2RXRARXRBRXRG | |
| Water SCHEMBL28675682 | 0.62 | PGK1 (0.47) | ACP3CES2PGK1PGK2CA12 | |
| SCHEMBL440959 | 0.62 | CES2 (0.58) | CES2LMNARXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10315990-B2 | Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof | DRIVINGFORCE THERAPEUTICS (CN) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10315990-B2 | Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof | XPO1, XPOT, XPO4 | ACP3 4257/4885CES2 1521/4885PGK1 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.